Antiplatelet Treatment After Transient Ischemic Attack and Ischemic Stroke in Patients With Cerebral Microbleeds in 2 Large Cohorts and an Updated Systematic Review

Kui Kai Lau, Caroline E Lovelock, Linxin Li, Michela Simoni, Sergei Gutnikov, Wilhelm Küker, Henry Ka Fung Mak, Peter M Rothwell, Kui Kai Lau, Caroline E Lovelock, Linxin Li, Michela Simoni, Sergei Gutnikov, Wilhelm Küker, Henry Ka Fung Mak, Peter M Rothwell

Abstract

Background and purpose: In patients with transient ischemic attack/ischemic stroke, microbleed burden predicts intracerebral hemorrhage (ICH), and ischemic stroke, but implications for antiplatelet treatment are uncertain. Previous cohort studies have had insufficient follow-up to assess the time course of risks, have not stratified risks by antithrombotic use, and have not reported extracranial bleeds or functional outcome of ICH versus ischemic stroke.

Methods: In 2 independent prospective cohorts with transient ischemic attack/ischemic stroke (Oxford Vascular Study/mainly white; University of Hong Kong/mainly Chinese), antiplatelet treatment was started routinely irrespective of microbleed burden. Risks, time course and outcome of ICH, extracranial bleeds, and recurrent ischemic events were determined and stratified by microbleed burden (0 versus 1, 2-4, and ≥5), adjusting for age, sex, and vascular risk factors.

Results: Microbleeds were more frequent in the Chinese cohort (450 of 1003 versus 165 of 1080; P<0.0001), but risk associations were similar during 7433 patient-years of follow-up. Among 1811 patients on antiplatelet drugs, risk of major extracranial bleeds was unrelated to microbleed burden (Ptrend=0.87), but the 5-year risk of ICH was steeply related (Ptrend<0.0001), with 11 of 15 (73%) of ICH in 140 of 1811 (7.7%) patients with ≥5 microbleeds. However, risk of ischemic stroke also increased with microbleed burden (Ptrend=0.013), such that risk of ischemic stroke and coronary events exceeded ICH and major extracranial bleeds during the first year, even among patients with ≥5 microbleeds (11.6% versus 3.9%). However, this ratio changed over time, with risk of hemorrhage (11.2%) matching that of ischemic events (12.0%) after 1 year. Moreover, whereas the association between microbleed burden and risk of ischemic stroke was due mainly to nondisabling events (Ptrend=0.007), the association with ICH was accounted for (Ptrend<0.0001) by disabling/fatal events (≥5 microbleeds: 82% disabling/fatal ICH versus 40% disabling/fatal ischemic stroke; P=0.035).

Conclusions: In white and Chinese patients with ≥5 microbleeds, withholding antiplatelet drugs during the first year after transient ischemic attack/ischemic stroke may be inappropriate. However, the risk of ICH may outweigh any benefit thereafter.

Keywords: cerebral small vessel disease; magnetic resonance imaging; stroke; transient ischemic attack.

© 2018 The Authors.

Figures

Figure 1.
Figure 1.
Risk of recurrent stroke (A), recurrent ischemic stroke (B), intracerebral hemorrhage (C), and intracerebral hemorrhage and major extracranial bleeding (D) among patients with transient ischemic attack/ischemic stroke on antiplatelets.
Figure 2.
Figure 2.
Risk of disabling or fatal (A) and nondisabling (B) ischemic stroke and intracerebral hemorrhage by microbleed burden in patients with transient ischemic attack/ischemic stroke on antiplatelets.
Figure 3.
Figure 3.
Risk of ischemic and hemorrhagic events in transient ischemic attack/ischemic stroke patients with

Figure 4.

Pooled analyses of relative risk…

Figure 4.

Pooled analyses of relative risk estimates from the current and previous studies showing…

Figure 4.
Pooled analyses of relative risk estimates from the current and previous studies showing risk of recurrent ischemic stroke (A) and of intracerebral hemorrhage (B) among patients with transient ischemic attack/ischemic stroke on antiplatelet agents with microbleeds vs those without, stratified by geographical origin, magnetic resonance imaging (MRI) scanner magnet strength, MRI sequence, and number of microbleeds. CI indicates confidence interval; GRE, gradient-recalled echo; HKU, University of Hong Kong; OXVASC, Oxford Vascular Study; RR, relative risk; and SWI, susceptibility weighted imaging.
Figure 4.
Figure 4.
Pooled analyses of relative risk estimates from the current and previous studies showing risk of recurrent ischemic stroke (A) and of intracerebral hemorrhage (B) among patients with transient ischemic attack/ischemic stroke on antiplatelet agents with microbleeds vs those without, stratified by geographical origin, magnetic resonance imaging (MRI) scanner magnet strength, MRI sequence, and number of microbleeds. CI indicates confidence interval; GRE, gradient-recalled echo; HKU, University of Hong Kong; OXVASC, Oxford Vascular Study; RR, relative risk; and SWI, susceptibility weighted imaging.

References

    1. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007;130:1988–2003.
    1. Fisher M. Cerebral microbleeds: where are we now? Neurology. 2014;83:1304–1305. doi: 10.1212/WNL.0000000000000871.
    1. van Veluw SJ, Biessels GJ, Klijn CJ, Rozemuller AJ. Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy. Neurology. 2016;86:867–871. doi: 10.1212/WNL.0000000000002419.
    1. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T, et al. Edinburgh Stroke Study Group. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010;41:1222–1228. doi: 10.1161/STROKEAHA.109.572594.
    1. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke. 2013;44:995–1001. doi: 10.1161/STROKEAHA.111.000038.
    1. Wilson D, Charidimou A, Ambler G, Fox ZV, Gregoire S, Rayson P, et al. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis. Neurology. 2016;87:1501–1510. doi: 10.1212/WNL.0000000000003183.
    1. Naka H, Nomura E, Kitamura J, Imamura E, Wakabayashi S, Matsumoto M. Antiplatelet therapy as a risk factor for microbleeds in intracerebral hemorrhage patients: analysis using specific antiplatelet agents. J Stroke Cerebrovasc Dis. 2013;22:834–840. doi: 10.1016/j.jstrokecerebrovasdis.2012.06.001.
    1. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388:365–375. doi: 10.1016/S0140-6736(16)30468-8.
    1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. doi: 10.1136/bmj.324.7329.71.
    1. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129–133. doi: 10.1161/01.STR.0000196991.03618.31.
    1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke. a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e110. doi: 10.1161/STR.0000000000000158.
    1. Wilson D, Werring DJ. Antithrombotic therapy in patients with cerebral microbleeds. Curr Opin Neurol. 2017;30:38–47. doi: 10.1097/WCO.0000000000000411.
    1. Lau KK, Wong YK, Teo KC, Chang RSK, Tse MY, Hoi CP, et al. Long-term prognostic implications of cerebral microbleeds in chinese patients with ischemic stroke. J Am Heart Assoc. 2017;6:e007360. doi: 10.1161/JAHA.117.007360.
    1. Kakar P, Charidimou A, Werring DJ. Cerebral microbleeds: a new dilemma in stroke medicine. JRSM Cardiovasc Dis. 2012;1:2048004012474754. doi: 10.1177/2048004012474754.
    1. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007;6:1063–1072. doi: 10.1016/S1474-4422(07)70274-0.
    1. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925–1933. doi: 10.1016/S0140-6736(04)16405-2.
    1. Lau KK, Li L, Lovelock CE, Zamboni G, Chan TT, Chiang MF, et al. Clinical correlates, ethnic differences, and prognostic implications of perivascular spaces in transient ischemic attack and ischemic stroke. Stroke. 2017;48:1470–1477. doi: 10.1161/STROKEAHA.117.016694.
    1. Lau KK, Li L, Schulz U, Simoni M, Chan KH, Ho SL, et al. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology. 2017;88:2260–2267. doi: 10.1212/WNL.0000000000004042.
    1. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–1350. doi: 10.1212/WNL.0b013e3181dad605.
    1. Charidimou A, Peeters A, Fox Z, Gregoire SM, Vandermeeren Y, Laloux P, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke. 2012;43:2324–2330. doi: 10.1161/STROKEAHA.112.657759.
    1. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, et al. Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165–174. doi: 10.1016/S1474-4422(09)70013-4.
    1. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73:1759–1766. doi: 10.1212/WNL.0b013e3181c34a7d.
    1. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351–356. doi: 10.2214/ajr.149.2.351.
    1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–838. doi: 10.1016/S1474-4422(13)70124-8.
    1. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis. 2015;39:224–231. doi: 10.1159/000375153.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
    1. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc Dis. 2011;32:528–534. doi: 10.1159/000331466.
    1. Akoudad S, Ikram MA, Koudstaal PJ, Hofman A, Niessen WJ, Greenberg SM, et al. Cerebral microbleeds are associated with the progression of ischemic vascular lesions. Cerebrovasc Dis. 2014;37:382–388. doi: 10.1159/000362590.
    1. Fluri F, Jax F, Amort M, Wetzel SG, Lyrer PA, Katan M, et al. Significance of microbleeds in patients with transient ischaemic attack. Eur J Neurol. 2012;19:522–524. doi: 10.1111/j.1468-1331.2011.03522.x.
    1. Lim JS, Hong KS, Kim GM, Bang OY, Bae HJ, Kwon HM, et al. Cerebral microbleeds and early recurrent stroke after transient ischemic attack: results from the Korean Transient Ischemic Attack Expression Registry. JAMA Neurol. 2015;72:301–308. doi: 10.1001/jamaneurol.2014.3958.
    1. Stehling C, Wersching H, Kloska SP, Kirchhof P, Ring J, Nassenstein I, et al. Detection of asymptomatic cerebral microbleeds: a comparative study at 1.5 and 3.0 T. Acad Radiol. 2008;15:895–900. doi: 10.1016/j.acra.2008.01.013.
    1. Gregoire SM, Werring DJ, Chaudhary UJ, Thornton JS, Brown MM, Yousry TA, et al. Choice of echo time on GRE T2*-weighted MRI influences the classification of brain microbleeds. Clin Radiol. 2010;65:391–394. doi: 10.1016/j.crad.2010.01.004.
    1. Cheng AL, Batool S, McCreary CR, Lauzon ML, Frayne R, Goyal M, et al. Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds. Stroke. 2013;44:2782–2786. doi: 10.1161/STROKEAHA.113.002267.
    1. Microbleeds International Collaborative Network. Worldwide collaboration in the microbleeds international collaborative network. Lancet Neurol. 2016;15:1113–1114. doi: 10.1016/S1474-4422(16)30213-7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren